



#24052928

Analysis Report prepared for

Sample Company

123 Main Street
Midlothian, VA 23112

Phone: (804) 562-3435

Drugs of Abuse Sample Report

123 Main Street
Midlothian, VA 23112

Collected: **September 15, 2025**

Received: **September 16, 2025**

Reported: **September 19, 2025**

We would like to thank you for trusting Hayes Microbial for your analytical needs!

We received 2 samples by Drop Off in good condition for this project on September 16th, 2025.

The results in this analysis pertain only to this job, collected on the stated date, and should not be used in the interpretation of any other job. Information supplied by the customer can affect the validity of results. These results apply only to the samples as received. This report may not be duplicated, except in full, without the written consent of Hayes Microbial Consulting, LLC.

All information provided to Hayes Microbial is confidential information relating to our customers and their clients. We will not disclose, copy, or distribute any information verbally or written, except to those designated by the customer(s). We take confidentiality very seriously. No changes to the distribution list will be made without the express consent of the customer.

This laboratory bears no responsibility for sample collection activities, analytical method limitations, or your use of the test results. Interpretation and use of test results are your responsibility. Any reference to health effects or interpretation of mold levels is strictly the opinion of Hayes Microbial. In no event, shall Hayes Microbial or any of its employees be liable for lost profits or any special, incidental or consequential damages arising out of the use of these test results.

A handwritten signature in black ink that reads "Stephen N. Hayes".

Steve Hayes, BSMT(ASCP)
Laboratory Director
Hayes Microbial Consulting, LLC.



EPA Laboratory ID: VA01419



DPH License: #PH-0198

| Sample Number | 1 | 01 | | 4 | 2 | | |
|--------------------|----------------------------|---------------|-----------------|----------------------------|---------------|-----------------|--|
| Sample Name | Main Floor | | | Garage | | | |
| Analysis | Drug - Comprehensive Panel | | | Drug - Comprehensive Panel | | | |
| Sample Area/Volume | 100.00 cm2 | | | 100.00 cm2 | | | |
| | Limit | Concentration | | Limit | Concentration | | |
| Amphetamine | <LOQ | <250 pg | <250 pg/100cm² | <LOD | <100 pg | <100 pg/100cm² | |
| Cocaine | <LOD | <50.0 pg | <50.0 pg/100cm² | <LOD | <50.0 pg | <50.0 pg/100cm² | |
| Codeine | <LOD | <100 pg | <100 pg/100cm² | <LOD | <100 pg | <100 pg/100cm² | |
| Dihydrocodeine | <LOD | <50.0 pg | <50.0 pg/100cm² | <LOD | <50.0 pg | <50.0 pg/100cm² | |
| Fentanyl | <LOD | <10.0 pg | <10.0 pg/100cm² | DETECT | 244 pg | 244 pg/100cm² | |
| Heroin | <LOD | <100 pg | <100 pg/100cm² | <LOD | <100 pg | <100 pg/100cm² | |
| Hydrocodone | <LOD | <100 pg | <100 pg/100cm² | <LOD | <100 pg | <100 pg/100cm² | |
| Hydromorphone | <LOD | <200 pg | <200 pg/100cm² | <LOD | <200 pg | <200 pg/100cm² | |
| Ketamine | <LOD | <200 pg | <200 pg/100cm² | <LOD | <200 pg | <200 pg/100cm² | |
| LSD | <LOD | <200 pg | <200 pg/100cm² | <LOD | <200 pg | <200 pg/100cm² | |
| MDA | <LOD | <250 pg | <250 pg/100cm² | <LOD | <250 pg | <250 pg/100cm² | |
| MDMA | <LOD | <100 pg | <100 pg/100cm² | <LOD | <100 pg | <100 pg/100cm² | |
| Methamphetamine | DETECT | 3.46 µg | 3.46 µg/100cm² | <LOD | <100 pg | <100 pg/100cm² | |
| Morphine | <LOD | <100 pg | <100 pg/100cm² | <LOD | <100 pg | <100 pg/100cm² | |
| Oxycodone | <LOD | <250 pg | <250 pg/100cm² | <LOD | <250 pg | <250 pg/100cm² | |
| Oxymorphone | <LOD | <100 pg | <100 pg/100cm² | <LOD | <100 pg | <100 pg/100cm² | |
| PCP | <LOD | <100 pg | <100 pg/100cm² | <LOD | <100 pg | <100 pg/100cm² | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

<LOD: Analyte peak below Limit of Detection. <LOQ: Analyte peak detected but below Limit of Quantification. Analyte peak detected



Collected: Sep 15, 2025

Received: Sep 16, 2025

Reported: Sep 19, 2025

Revision: 2

Project Analyst:
David McDonald, PHR *David McDonald*

Date:
09 - 19 - 2025

Reviewed By:
Steve Hayes, BSMT *Stephen N. Hayes*

Date:
09 - 19 - 2025

Many states have established their own health criteria or standards, ranging from 0.05 to 1.5 $\mu\text{g}/100\text{ cm}^2$ (50-1500ng/100cm²). Some states focus on methamphetamine contamination from manufacturing operations (clandestine drug laboratories), while others also address contamination from methamphetamine use.

| | |
|--|--|
| Methamphetamine | 0.05 $\mu\text{g}/100\text{ cm}^2$ (50ng/100cm ²): Oregon and Arkansas |
| | 0.1 $\mu\text{g}/100\text{ cm}^2$ (100ng/100cm ²): Minnesota (for former labs) and Oklahoma |
| | 0.5 $\mu\text{g}/100\text{ cm}^2$ (500ng/100cm ²): Indiana and Michigan, Arapahoe County. Colorado Public Health states their contamination threshold for residential space is 0.5 micrograms of meth per 100 square centimeters. |
| | 1.0 $\mu\text{g}/100\text{ cm}^2$ (1000ng/100cm ²): Montana, West Virginia and Utah |
| | 1.5 $\mu\text{g}/100\text{ cm}^2$ (1500ng/100cm ²): California and Washington state |
| * All other abuse drugs currently have no Federal or state regulatory limits * | |

Analyte Descriptions

| | |
|-----------------|--|
| Amphetamine | Description: A stimulant that increases heart rate and blood pressure, with risks of anxiety, tremors, and insomnia. Prolonged misuse can result in cardiovascular damage and psychiatric disorders. |
| | Category: Schedule II |
| Fentanyl | Description: A synthetic opioid 50–100 times more potent than morphine. Even microgram amounts can cause fatal respiratory arrest; accidental exposure is extremely dangerous. |
| | Category: Schedule II |
| Methamphetamine | Description: A powerful central nervous system stimulant associated with insomnia, aggression, paranoia, and severe dental and skin problems. Chronic use can cause neurotoxicity, cardiovascular damage, and stroke. |
| | Category: Schedule II |